Trial Profile
A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Celltrion
- 10 Jun 2019 Results assessing efficacy and safety of CT-P10 published in the Rheumatology.
- 05 Feb 2019 Results (up to week 48 ) assessing the long-term efficacy, pharmacodynamics, immunogenicity, and safety of extended treatment with CT-P10, were published in the BioDrugs Journal.
- 24 Oct 2018 Results assessing radiographic joint damage progression and its association with disease activity, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting